In the realm of neonatal care, phototherapy stands as a cornerstone treatment for jaundice—a common condition characterized by elevated levels of unconjugated bilirubin in full-term newborns. While the efficacy of phototherapy in reducing bilirubin levels and preventing severe neurological damage is well established, emerging research reveals an unexpected dimension to this widely used intervention: its impact on the neonatal heart. A groundbreaking study published in Pediatric Research reveals that phototherapy may induce myocardial dysfunction in full-term infants, underscoring the intricacy of balancing therapeutic benefit against potential cardiovascular risks.
Phototherapy, which involves exposing infants to specific wavelengths of light to catalyze the breakdown of bilirubin, is routinely employed in neonatal units globally. The study conducted by El Amrousy et al. delves into the nuanced relationship between the duration and intensity of phototherapy and subsequent alterations in cardiac function. According to their findings, prolonged exposure and increased numbers of phototherapy units correlate with measurable cardiac disturbances, suggesting that the therapy’s influence extends beyond hepatic metabolism into cardiac physiology.
This revelation prompts a critical reassessment of current neonatal phototherapy protocols. Traditionally, discussions around phototherapy’s side effects have centered on skin rash, dehydration, or retinal damage, with little attention paid to myocardial implications. The study’s findings compel clinicians to reevaluate the duration and intensity of phototherapy sessions, raising the possibility that the myocardium in neonates might be vulnerable to oxidative or inflammatory stress induced by phototherapeutic light exposure.
The cardiac dysfunction observed was characterized by changes in myocardial contractility and subtle alterations in cardiac output, detected through advanced echocardiographic indices. These changes, although transient in nature, may portend longer-term sequelae if not appropriately monitored. The pathophysiological mechanisms proposed involve a complex interplay between phototherapy-related oxidative stress and the immature cardiac cellular environment of neonates, which lacks robust antioxidant defenses.
Notably, the study underscores that the risk of cardiac dysfunction rises with both the cumulative duration of phototherapy and the number of phototherapy units employed simultaneously. This dose-dependent relationship highlights that while phototherapy remains indispensable for treating hyperbilirubinemia, there exists a threshold beyond which the cardiac muscle’s integrity may be compromised. It also raises the question of whether newer phototherapy devices that emit light at optimized wavelengths or intensities could mitigate these adverse effects.
In response to these findings, the concept of cardiac shielding during phototherapy gains renewed attention. Traditional approaches to phototherapy focus primarily on protecting the eyes; however, shielding the thoracic area could serve as a preventive measure against inadvertent myocardial exposure to phototherapeutic light. Implementation of such shielding protocols would necessitate rigorous clinical trials to validate their efficacy and ensure that bilirubin reduction is not compromised.
Beyond the immediate clinical implications, this research invites a broader discussion on neonatal vulnerability. The neonatal period is marked by rapid maturation and fragile organ systems, and treatments designed to correct one physiological imbalance might inadvertently perturb others. The myocardium’s plasticity and susceptibility during this critical window may render it uniquely sensitive to environmental factors, including therapeutic interventions like phototherapy.
These findings also prompt a reevaluation of monitoring standards during phototherapy. Incorporating routine cardiac function assessments via echocardiography or advanced cardiac imaging might become a necessary adjunct to standard bilirubin monitoring. Early detection of myocardial changes would enable clinicians to tailor phototherapy regimens, balancing efficacy and safety more precisely.
Moreover, the interplay between phototherapy-induced oxidative stress and myocardial cell function warrants further molecular investigation. Understanding the biochemical cascades triggered within cardiac myocytes could identify novel protective agents or interventions that minimize cardiac stress without diminishing phototherapy’s beneficial effects. Antioxidant supplementation or pharmacological cardioprotective strategies could emerge as adjuncts in neonatal jaundice management.
This study’s findings resonate beyond neonatology, illustrating the delicate equilibrium inherent in pediatric therapeutic interventions. The fine line between treatment benefit and potential adverse effects is especially consequential in developing organ systems. As technologies evolve and treatment paradigms advance, continuous vigilance is required to uncover and mitigate unforeseen complications.
Furthermore, the study raises foundational questions about the biophysical mechanisms through which phototherapy interacts with cardiac tissues. While light-induced bilirubin metabolism is well elucidated, the pathways through which photons affect myocardial cells remain poorly understood. This could open new research avenues exploring photobiomodulation effects on the heart, potentially influencing not only neonatal care but broader medical phototherapy applications.
In clinical practice, these insights necessitate multidisciplinary collaboration between neonatologists, cardiologists, and biomedical engineers to optimize phototherapeutic devices and protocols. Designing equipment that maximizes bilirubin breakdown while minimizing scatter light reaching the thorax could become a priority. Similarly, clinical guidelines may evolve to recommend cardiac function evaluation before, during, and after phototherapy, especially for infants requiring prolonged or intensive sessions.
Additionally, healthcare providers may need to educate parents about potential cardiac considerations during phototherapy, fostering informed consent discussions that transparently address both benefits and risks. Integrating parental perspectives will be crucial in shaping guidelines that balance therapeutic urgency with safety concerns.
The study’s limitations, including the need for larger cohorts and long-term follow-up, also highlight the importance of replicating and expanding these findings. Longitudinal studies tracking infants exposed to extensive phototherapy could clarify whether observed myocardial changes resolve fully or contribute to subtle cardiac dysfunction later in life.
To sum up, the emerging evidence positions phototherapy as a double-edged sword—an essential treatment for neonatal jaundice with an under-recognized potential for myocardial impact. This recognition heralds a new chapter in neonatal care, where phototherapy is not only assessed for efficacy in bilirubin reduction but also scrutinized for cardiovascular safety. With vigilant monitoring, innovative device design, and targeted protective strategies, the neonatal community can continue to harness phototherapy’s life-saving potential while safeguarding the delicate newborn heart.
Subject of Research: Effect of phototherapy on cardiac function in full-term neonates with unconjugated hyperbilirubinemia
Article Title: Effect of phototherapy on cardiac function in full term neonates with unconjugated hyperbilirubinemia
Article References:
El Amrousy, D., Adel, R., Ayoub, D. et al. Effect of phototherapy on cardiac function in full term neonates with unconjugated hyperbilirubinemia. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04071-4
Image Credits: AI Generated
